High‐Throughput Screening of Cell Transfection Enhancers Using Miniaturized Droplet Microarrays by Liu, Yanxi et al.
www.adv-biosys.com
© 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1900257 (1 of 12)
Full PaPer
High-Throughput Screening of Cell Transfection Enhancers 
Using Miniaturized Droplet Microarrays
Yanxi Liu, Tina Tronser, Ravindra Peravali, Markus Reischl, and Pavel A. Levkin*
DOI: 10.1002/adbi.201900257
gene disorders, infection, and cancers.[5] 
However, many nonviral transfection 
reagents have relatively low transfection 
efficiency as they are usually hindered by 
numerous extra- and intracellular obsta-
cles.[6] Many researchers focused on this 
field and developed various gene delivery 
vehicles to achieve safe, efficient, and con-
trollable gene delivery, including biode-
gradable nanoparticles,[7] polymer-based 
gene delivery systems,[8] stimuli-responsive 
nanocarriers,[9] lipid-based vectors,[10] and 
polypeptides-based vectors.[11] Although 
these methods have advantages in terms of 
nonimmunogenicity and nononcogenicity 
of vectors, most of these approaches suffer 
from poor efficiency of delivery and tran-
sient expression of the gene. In addition, 
one of the drawbacks of these approaches 
is the diminished specificity of these mate-
rials.[12] A lot of the current gene-therapy 
approaches make use of viral vectors. 
Nevertheless, humans have an immune 
system to fight off the virus, resulting in 
the safety concerns of viral gene delivery.[3b] 
In vivo and in vitro gene delivery has also been traditionally hin-
dered by the toxicity associated with their formulation.[13]
In 1983, Luthman et al. reported that exposure to chloroquine 
increased the proportion of transfected mouse cells to ≈40%.[14] 
Afterward, several researchers reported neomycin,[15] dexametha-
sone,[16] and nocodazole[17] also made a contribution to the trans-
fection efficiency enhancement. Hence, in the present project, we 
hypothesized that by treating cells with small molecules, the trans-
fection efficiency can be improved in a safe and controllable way. 
Nevertheless, in order to identify such transfection-enhancing 
molecules, thousands of structurally diverse molecules must be 
tested. Current high-throughput screening (HTS) technologies 
DNA delivery is a powerful research tool for biological research and clinical 
therapies. However, many nonviral transfection reagents have relatively 
low transfection efficiency. It is hypothesized that by treating cells with 
small molecules, the transfection efficiency can be improved. However, 
in order to identify such transfection-enhancing molecules, thousands 
of molecules must be tested. Current high-throughput screening (HTS) 
technologies based on microtiter plates are not suitable for such screenings 
due to the prohibitively high costs of reagents and operation. Here, the 
use of the droplet microarray (DMA) platform to screen 774 FDA-approved 
drugs with CHO-K1, Jurkat and HEK293T cells is reported. The volume 
of individual aqueous compartments is 20 nL, requiring 0.84 mL of cell 
suspension and 200 pmoles of each drug (total 0.02 moles) to perform the 
screening. Thus, the requirement for cells and reagents is 2500 times less 
than that for the same experiment performed in 384-well plates. The results 
reveal the potential of the DMA platform as a more cost-effective and less 
labor-intensive approach to HTS. Furthermore, an increase (approximately 
two- to fivefold) in transfection efficiency is achieved by treating cells with 
some molecules. This study clearly demonstrates the potential of the DMA 
platform for miniaturization of biochemical and cellular HTS.
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1. Introduction
Over the past 30 years, large significant efforts have been dedi-
cated to develop nanotechnology by which various molecules 
or macromolecules, such as proteins,[1] peptides,[2] and genes[3] 
can be successfully targeted to sites of interests. DNA delivery, 
especially via the nonviral route (i.e., gene transfection), has 
become a powerful research tool for elucidating gene struc-
ture, regulation, and function.[4] DNA delivery has been pivotal 
in developing new approaches (e.g., gene therapy and DNA 
vaccination) for biological research and new clinical therapies. 
Gene therapy provides a great opportunity to treat diseases from 
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based on microtiter plates cannot be used in such screenings due 
to prohibitively high costs associated with large volumes of rea-
gent and the man-power required.[18]
In the last decades, a great deal of effort has been made to 
develop innovative miniaturized platform for biological screening, 
including inkjet printing,[19] microfluidic technology,[20] cell-
based microarrays,[21] and nanowell array chip.[22] The chip array 
based on inkjet printing technique can be used to develop up to 
hundreds of picoliter aqueous droplet arrays and can be further 
applied to do biological assays, such as luminometric detection 
and protein binding assays.[19] However, the compatibility of cells 
within such a tiny volume need to be further investigated and 
the employment of oil phase might influence its application with 
cells. The microfluidic-based chip and nanowell array chip could 
be used to establish 2D or 3D in vitro cell culture model systems 
for cell cytotoxicity screening and real-time drug delivery moni-
toring.[20,22] Nevertheless, the involvement of oil phase might 
restrict its applicability and high-throughput applications. Cell-
based microarrays introduced by Sabatini allow high-throughput 
screening in a highly miniaturized format.[21] However, the trans-
fection mixtures need to be preprinted onto the glass slides or 
arrays, and the slides have to be immersed into one medium, 
which means they cannot have separate compartments after cell 
seeding. The small drug molecules can freely diffuse within the 
medium, resulting in cross-contamination.
Our group has recently developed the droplet microarray 
(DMA) platform based on the superhydrophobic–hydrophilic 
surfaces,[23] which can be applied to high-throughput screenings 
of live cells in 2D and 3D,[24] including cytotoxicity screening, 
embryoid bodies screening, tumor spheroids screening, and zebra 
fish embryo screening. However, such large screening (41796 
individual experiments) with extremely small volumes (20 nL) has 
never been done so far. This ultrahigh throughput and miniaturi-
zation impose completely new challenges to the droplet micro-
array platform, which we aimed to investigate in this work using 
cell transfection as a crucial biological tool used in drug discovery 
and related fields. High-density arrays of nanoliter sized droplets 
with defined shapes could be formed on this superhydrophobic–
hydrophilic transparent layer on the glass slide. The DMA plat-
form has the following advantages: a) three orders of magnitude 
less cells and reagents; b) compatibility with cells in different char-
acteristics, such as adherent and suspension cells; c) avoid cross-
contamination combining with the noncontact printer; d) less pipet-
ting manipulation; and e) applicability to ultrahigh-throughput 
screening. Furthermore, the drugs can be dried on each indi-
vidual spots for multiple detection for different read-out which 
makes the DMA platform more flexible for multiple applications. 
The separate individual spots also raise the possibility to repeat-
edly add solutions or cells without any cross-contamination since 
the liquid can be printed precisely into each individual spot. By 
adjusting the size of spots, a higher-throughput can also be 
achieved. Compared to conventional experiments conducted in 
microtiter plates, such as 384- and 96-well plates, screening on 
our DMA could lead to around 2500-fold costs saving compared to 
experiments conducted in 384-well plates.
In this study, we investigated the influence of 774 Food and 
Drug Administration (FDA)-approved drugs on transfection 
efficiency with CHO-K1, Jurkat and HEK293T cells. We per-
formed a screening of the drugs using the DMA platform in 
three concentrations with triplicates based on two cell lines and 
repeated three times, resulting in a total of 41 796 individual 
experiments. The volume of individual aqueous compartments 
was 20 nL, requiring only 0.84 mL of total cell suspension 
and 200 pmoles of each drug (total 0.02 moles) to perform the 
screening. Thus, the requirement for the cells and reagents was 
2500 times less than that for the same experiment performed in 
384-well plates. The results reveal the potential of the DMA plat-
form as a more cost-effective and less labor-intensive approach to 
HTS, making this technology a viable option in a standard biology 
laboratory. Furthermore, we achieved an increase (approximately 
2-5-fold) in transfection efficiency by treatment of the cells with 
some small molecules (auranofin, carbidopa, captopril, hydro-
cortisone acetate, ifosfamide, indapamide, oxacillin sodium salt 
monohydrate, methylprednisolone, naphazoline·HCl, rifampin, 
oxiconazole nitrate, piroxicam, tranylcypromine hemisulfate 
and rivastigmine tartrate) approved for other indications. This 
was confirmed in standard transfection experiments in 384- and 
96-well plates with CHO-K1 and HEK293T cells. This study 
clearly demonstrates the potential of the DMA platform for min-
iaturization of biochemical and cellular HTS.
2. Results and Discussion
2.1. Establishment of an HTS Assay for CHO-K1 and Jurkat Cells
DMA slide is a glass slide patterned with an array of hydro-
philic spots assigned by superhydrophobic borders based 
on certain substrate. We used different DMA slides with a 
dimension of 7.5 × 2.5 cm divided into three square fields (left 
field, center field, and right field) containing 588 (1 mm side 
length of square spots) and 2187 (500 µm side length of 
square spots) individual spots (Figure 1A; and Figure S1, 
Supporting Information). Because of the precise patterned 
square spots and stable borders, homogeneous cellular micro-
arrays can be created by printing cell suspensions directly into 
each individual spot using a noncontact cell printer and further 
incubated for determined time (Figure 1B). The efficiency of 
transfection can be analyzed using regular fluorescence micros-
copy (Figure 1C). Beyond that, this system is also accessible for 
culturing and transfecting cells with different characteristics, 
such as adherent and suspension cells (Figure 1D–F).
In order to identify drug candidates that can potentially 
enhance transfection efficiency and/or increase the numbers of 
green fluorescent protein (GFP)-expressing cells, we developed 
an HTS assay that can rapidly screen numerous compounds. 
As for cell systems, we chose CHO-K1 cells, Jurkat, and 
HEK293T cells. CHO-K1 cells are one of the most important 
cell lines for the production of biotherapeutic protein and anti-
bodies, but they are typically difficult to transfect. Jurkat cells 
are an immortalized line of human T lymphocyte which are 
widely used due to their relevance to blood cells. And HEK293T 
cells are a standard cell line used by many scientists because of 
their propensity for transfection.
A schematic of the HTS workflow is depicted in Figure 2; 
and Figure S2 (Supporting Information). In the first step, the 
stock solution of 774 FDA-approved drugs were diluted to three 
concentrations 1, 10, and 30 × 10−6 m, and then 20 nL of each 
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drug was printed on 500 µm DMA slides. After drug printing, 
certain amount of dimethyl sulfoxide (DMSO) were still in each 
spot, which was toxic for the cells. To remove DMSO from the 
spots and to make all the conditions the same during printing, 
the slides were dried in a vacuum desiccator overnight. Com-
plexes of GFP plasmid DNA and ScreenFectA transfection rea-
gent were prepared and then printed into each spot and incu-
bated with drugs at three concentrations along with a drug-free 
control (DMSO). And the same three controls were located at 
each square field inside of each slide. Besides, the outer two 
rows and columns were subtracted because of the edge effect. 
After 24 h incubation, cells were fixed, and the GFP expressed 
cells were imaged by an automated fluorescence microscope 
and the number of GFP-positive cells was quantified. Then the 
relative transfection enhancement was calculated as a ratio of 
the mean number of GFP positive cells for each drug over the 
mean number of GFP positive cells of drug-free controls. Heat-
maps in Figure 3A demonstrate the result of primary screening 
of CHO-K1 cells. The blue cells of the heatmap represent wells 
with less GFP positive cells than that in the drug-free control 
wells, while the red color represents experiments with more GFP 
positive cells than that in the drug-free controls. For CHO-K1 
cells, there were 425 compounds which showed transfection 
enhancement, while 349 compounds showed transfection 
decrease at the concentration of 1 × 10−6 m when compared to 
drug-free controls. As for 10 × 10−6 m, 624 compounds showed 
transfection enhancement while 150 compounds showed trans-
fection decrease. At 30 × 10−6 m, the numbers of the transfec-
tion enhancement and transfection decrease were 233 and 541, 
respectively. The transfection enhancement demonstrated a 
concentration-dependent manner and at the concentration of 
10 × 10−6 m, the most drugs showed transfection enhancement 
compared to the concentration of 1 and 30 × 10−6 m. It might 
be that the drugs have various influence on the cellular endocy-
tosis, intracellular delivery and localization of the transfection 
complex, resulting in a different expression of GFP followed by 
different transfection efficiency. Primary hits (hit compounds) 
were identified as drugs that increased the number of GFP 
positive cells in comparison to the drug-free mean by at least 
three standard deviations. Thus, at 1 × 10−6 m concentration, 
19 hits were identified, as well as 78 hits at 10 × 10−6 m con-
centration and 18 hits at 30 × 10−6 m concentration (Figure 4). 
Seven compounds (auranofin, captopril, tranylcypromine 
hemisulfate, piroxicam, carbidopa, oxacillin sodium salt mono-
hydrate, and oxiconazole nitrate) showed repeatable transfec-
tion enhancement at different concentrations. There are more 
Adv. Biosys. 2020, 4, 1900257
Figure 1. A) Representative image of 1 mm (square side length is 1 mm) droplet microarray (DMA) with 588 individual microdroplets. Size of the 
DMA slide is 7.5 ± 2.5 cm. B) Bright field microscope image showing morphology of CHO-K1 cells after 24 h incubation (scale bar: 100 µm). C) Repre-
sentative image of HEK293T cells transfected with GFP plasmid DNA on the droplet microarray with 1 mm spot size (scale bar: 1 mm). Fluorescence 
microscope images of individual microdroplets of D) HEK293T cells, E) CHO-K1 cells, and F) Jurkat suspension cells transfected with GFP plasmid 
DNA (scale bar: 100 µm).
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hits at 10 × 10−6 m than at 1 × 10−6 m, it might be the stimuli 
from the drugs at low concentration increases the cell division 
activity which could lead to the negative results. There are more 
hits at 10 × 10−6 m concentration than at 30 × 10−6 m, which can 
be explained by increased toxicity at the highest concentration 
used and, thus lower overall cell number per experiment.
Furthermore, a principal component analysis (PCA) based 
multiobjective optimization procedure was also utilized for 
double verification of the screening results to get rid of false 
signals and for the dimensionality reduction, whose efficacy was 
demonstrated by solving up to 50-objective optimization prob-
lems.[25] In the PCA score plot (Figure 3B), each number repre-
sented one drug and significantly different behaviors of transfec-
tion under different drugs can be observed. The GFP expressed 
cell numbers vary in the presence of drugs, resulted in drugs 
that were distinct from the transfection under control condi-
tions. The outliers (hit compounds) got from the PCA analysis 
are almost the same as identified using the above algorithm.
Adv. Biosys. 2020, 4, 1900257
Figure 2. The workflow of the primary cell screening. A) 774 FDA approved drugs as DMSO solutions were printed on 500 µm DMA slides and dried 
in the vacuum desiccator overnight. Cells mixed with the transfection mixture (ScreenFectA transfection reagent, GFP plasmid DNA) were then printed 
into each spot and incubated with drugs for 24 h before fixation and fluorescence microscopy analysis. Final concentrations of drugs in the were 1, 
10, and 30 × 10−6 m. 14 hit compounds from primary screening were printed onto the 1 mm DMA slides and the procedure was repeated in the same 
way, except for the use of larger concentration ranges: 1, 5, 10, 20, 30, and 40 × 10−6 m. For the drug-free control experiments, the transfection mixtures 
were printed into empty spots. B) The process of high-throughput screening designed for transfection enhancers screening. The primary screening 
was conducted on 500 µm DMA slides (20 nL per experiment) and the secondary screening was done on 1 mm DMA slides (100 nL per experiment). 
Further validation and comparison was carried out in conventional high-throughput screening platform 384-well plates. Finally, the hits were confirmed 
in 96-well plates under optimized conditions. C) Screening of 774 FDA-approved drugs in three concentrations, resulted in a total of 41 796 individual 
experiments. The volume of individual aqueous compartments was 20 nL, which in total resulted in only 0.84 mL of total cell suspension and require 
only 200 pmoles of drugs (total 0.02 moles), which is 2500 times smaller than if the same experiment would have to be performed in 384-well plates.
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The same primary screening was also conducted with Jurkat 
human T-cell lymphocyte cells, which has traditionally proven 
to be very difficult to transfect due to a reduced attachment of 
the transfection complex to the surface of cells.[26] The results 
of the primary screening of Jurkat cells showed significantly 
less positive hits in comparison to the transfection of CHO-K1 
cells (Figure S5 and Table S1, Supporting Information). For 
Jurkat cells, there were 244 compounds which showed transfec-
tion enhancement while 530 compounds showed transfection 
decrease at the concentration of 1 × 10−6 m when compared to the 
drug-free controls. As for 10 × 10−6 m, 325 compounds showed 
transfection enhancement while 449 compounds showed 
transfection decrease. At 30 × 10−6 m, the numbers of the trans-
fection enhancement and transfection decrease were 192 and 
582, respectively. Due to the difficult transfection characteristic 
of Jurkat cells, less transfection enhancement compounds could 
be found compared to CHO-K1 cells. When the threshold of the 
primary screening was set as mean + 3SD, no hits were identi-
fied at 1 × 10−6 m concentration. But 2 hits at 10 × 10−6 m con-
centration and 1 hit at 30 × 10−6 m concentration were identified 
(Figure S5 and Table S1, Supporting Information). The higher 
overall transfected cell number demonstrates six- to eightfold 
relative transfection enhancement of the two hits compared to 
the drug-free controls in the primary screening.
Adv. Biosys. 2020, 4, 1900257
Figure 3. The impact of FDA-approved drugs on the efficiency of transfection of CHO-K1 cells. A) Heat maps generated using the quantified relative 
transfection efficiency data from 20 898 total transfection experiment (three biological repeats and three replicates each time). The blue and red colors 
indicate either decrease or increase of efficiency, respectively, in comparison to the controls without addition of drugs. Three different drug concentra-
tions were used: 1, 10, and 30 × 10−6 m. B) Overview of primary screening results using the principal component analysis (PCA) score plot. Each number 
represents one drug from the FDA-approved drug library.
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2.2. Validation of Primary Hits as Transfection Enhancers
In the primary screening, we assumed that the numbers of 
cells printed onto each individual spot are the same. Neverthe-
less, cells will precipitate during printing due to the printing 
pressure and gravity, resulting in the variability of cell num-
bers among spots (Figure S3, Supporting Information). For 
this reason, the hits from the primary screening were further 
validated. We selected 14 compounds that showed a strong 
enhancement effect at one concentration or showed repeat-
able positive enhancement at different concentrations for the 
secondary screening in order to validate the observed effects 
(Table 1; and Figure S4, Supporting Information). The valida-
tion experiment was performed in the 1 mm DMA (Figure 2B) 
at concentrations ranging from 1 to 40 × 10−6 m. To further test 
whether the transfection hits help in transfection efficiency 
enhancement, we introduced HEK293T, which is a well-known 
easy to transfect cell type,[27] to test the hits from the primary 
screening as well. Each drug was evaluated by three parame-
ters: 1) number of GFP expressing cells, 2) dead cell number 
(stained by PI), and 3) total cell numbers (stained by Hoechst 
33 342). Figure 5 demonstrates the transfection efficiency and 
cell viability for each drug. The secondary screening showed 
obvious and reproducible dose-dependent effects of the drugs 
on transfection efficiency. Transfection efficiencies increased 
between 1.8-fold to 5.1-fold compared to drug-free control. 
However, 12 out of 14 hits showed considerable transfection 
efficiency reduction at higher drug concentrations due to the 
high toxicity toward cells (30 and 40 × 10−6 m). In the case of 
piroxicam and tranylcypromine hemisulfate, the transfection 
enhancement is observed even at higher concentrations. Some 
drugs (ifosfamide, methylprednisolone, and oxacillin sodium 
salt monohydrate) showed the same trend in the primary 
screening and the secondary screening. All 14 compounds also 
demonstrated a dose-dependent negative effect on cell viability 
of CHO-K1 cells.
Adv. Biosys. 2020, 4, 1900257
Figure 4. Hit compounds identified as transfection enhancers in the primary screening of CHO-K1 cells. A)19 out of 774 FDA-approved drugs obtained 
from primary screening at 1 × 10−6 m concentration of CHO-K1 cells. B) 78 hit compounds identified at 10 × 10−6 m concentration. C) Scatter plot of 
18 hit compounds obtained from primary screening at 30 × 10−6 m of CHO-K1 cells. The red color indicated the compounds (auranofin, captopril, 
tranylcypromine hemisulfate, piroxicam, carbidopa, oxacillin sodium salt monohydrate, and oxiconazole nitrate) that showed repeatable positive 
enhancement at different concentrations and the green color indicated the compounds (rifampin, rivastigmine tartrate, hydrocortisone acetate, 
ifosfamide, indapamide, methylprednisolone, and naphazoline·HCl) that showed strong enhancement effect at one concentration. Data were presented 
as mean ± SD of three biological experiments with three technical repeats each time.
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The hits validation with Jurkat cells (Figure S6, Supporting 
Information) and HEK293T cells (Figure S7, Supporting Infor-
mation) are also presented. The results of HEK293T that is a 
well-known easy to cultivate and transfect cell type, also showed 
the same transfection efficiency enhancement trend as CHO-K1 
cells with higher absolute transfection efficiency (between 1.2-
fold to 3.5-fold increase compared to drug-free control). In the 
case of Jurkat cells, no significant transfection enhancement 
was observed at all concentrations tested, probably due to the 
overall too low transfection efficiencies.
In order to further validate the obtained results, we com-
pared the transfection efficiency of hits at their optimum 
concentrations on DMA (Table S2, Supporting Information) 
on both DMA slides and conventional 384-well plates of 
CHO-K1 cells (Figure 6) and HEK293T cells (Figure S8, Sup-
porting Information). In general, the transfection efficiency 
Adv. Biosys. 2020, 4, 1900257
Table 1. 14 Hit compounds selected from the primary screening.
Compound Therapeutic effect Structure Compound Therapeutic effect Structure






Carbidopa Inhibitor of DOPA 
decarboxylase
Rivastigmine tartrate Inhibitor of parasympath-
omimetic and 
cholinesterase
Auranofin Inhibitor of kappaB kinase 
and thioredoxin reductase
Hydrocortisone acetate Antiinflammatory or 
immunosuppressive drug
Oxiconazole nitrate Antibiotic used in resistant 
staphylococci infections





Inhibitor of monoamine 
oxidase (MAO)
Indapamide Antihypertensive and 
diuretic agent
Piroxicam Inhibitor of cyclooxygenase, 
nonsteroidal antiinflamma-
tory agent (NSAID)
Methylprednisolone Antiinflammatory and 
immunosuppressive 
agent




Naphazoline·HCl Sympathomimetic alpha 
adrenergic agonist
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Figure 5. Impact of 14 hit compounds on GFP plasmid DNA transfection of CHO-K1 cells. Different amounts of fourteen hit compounds (auranofin, 
carbidopa, captopril, hydrocortisone acetate, ifosfamide, indapamide, oxacillin sodium salt monohydrate, methylprednisolone, naphazoline·HCl, 
rifampin, oxiconazole nitrate, piroxicam, tranylcypromine hemisulfate, and rivastigmine tartrate) were printed onto 1 mm DMA, dried in the vacuum 
www.adv-biosys.comwww.advancedsciencenews.com
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of the individual wells in 384-well plates was less vari-
able than that on the individual spots on DMA, which can 
be attributed to the 11.35-fold less cells in each droplet of 
the DMA in comparison with the plate format (100 nL per 
spot and 100 cells per spot vs 20 µL per well and 1135 cells 
per well). While the average transfection efficiency showed 
no significant differences between the two platforms, 
confirming the validity of the results from the primary and 
secondary screening and the possibility to translate obtained 
results into larger, more commonly used formats, such as 
microtiter plates.
2.3. Validation of the Results under Optimal Conditions
Since DMA and conventional microtiter plates are two different 
in vitro cell culture systems in terms of the cell cultivation 
and experiment parameters might be diverse due to the dis-
crepancy in formats, edge-effects, evaporation, and area 
to volume ratio. The transfection parameters are also sup-
posed to be different. Therefore, we selected four hits (hydro-
cortisone acetate, naphazoline·HCl, oxacillin sodium salt 
monohydrate, and piroxicam) after validation and further 
evaluated the transfection efficiency in an optimal condition 
of transfection in 96-well plates. First, the transfection optimi-
zation in the presence or absence of the drugs was conducted 
according to the manufacturer’s instruction (Figure S9A–E, 
Supporting Information) using transfection reagent amounts 
from 0.1 to 0.4 µL/96-well plate well and from 50 to 100 ng 
per well of plasmid DNA. As shown in Figure S9 (Supporting 
Information), the highest transfection efficiency was achieved 
at 0.4 µL transfection reagent with 100 ng DNA per well with 
or without the drugs. Thus, these conditions were chosen for 
the following experiments. The transfection efficiency and cell 
viability were evaluated with these four drugs and compared 
with the drug-free control. As shown in Figure S9F (Supporting 
Information), naphazoline·HCl, oxacillin sodium salt mono-
hydrate, and piroxicam could increase the transfection effi-
ciency from 30.3% ± 1.6% (drug-free control) to 36.3% ± 0.9%, 
38.8% ± 1.1%, 33.9% ± 1.2%, respectively. It should be noted 
that the mechanisms behind the increase of transfection effi-
ciency caused by these molecules are still unknown and need 
further investigation. The transfection enhancement may be 
caused by the influence of these drugs on the expression of 
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Figure 6. The impact of hit compounds from primary screening under the best concentration in the individual spots on A) 1 mm DMA and in 
B) 384-well plates of CHO-K1 cells in all three analyzed replicates in both formats. Transfection efficiency in every image taken/per well (per spot) 
is shown separately. The different shapes indicate individual replicates (replicate 1-square, replicate 2-circle, and replicate 3-triangle). The optimal 
working concentrations of each drug according to the secondary screening were used for each drug (Table S2, Supporting Information). The transfec-
tion complexes were prepared with 0.017 µL ScreenFectA in 10 µL ScreenFect dilution buffer, followed by diluting a total of 17 ng GFP plasmid DNA 
in dilution buffer to a final volume of 10 µL (ratio of the ScreenFectA-to-plasmid DNA is 1:1). Then 80 µL fresh cell suspension at a concentration of 
7.13 × 104 cells mL−1 were added to complexes followed by mixing and seeding into each well at a volume of 20 µL per well. Data were presented as 
mean ± SD of three biological experiments with three technical repeats each time.
desiccator overnight, followed by printing pretransfected cells and incubation for 24 h in 100 nL droplets before quantification. Treatments were per-
formed at concentrations of 0, 1, 5, 10, 20, 30, and 40 × 10−6 m for each compound. After that, cells on DMA were stained with Hoechst 33 342 to 
visualize cell nuclei and propidium iodide (PI) to distinguish dead cells. DMA was then placed in a petri cell culture incubator for 15 min. Fluorescence 
images were taken using the Olympus IX81 inverted motorized microscope. The number of GFP positive, Hoechst 33 342 and PI-positive cells were 
counted using Image J. Cell viability was calculated using the following equation: cell viability (%) = 1 – (PI-positive cell numbers/Hoechst positive cell 
numbers) × 100. The transfection efficiency was calculated as follows: transfection efficiency (%) = (GFP positive cell numbers/Hoechst positive cell 
numbers) × 100. Data were presented as mean ± SD of three biological experiments with ten technical repeats each time.
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particular genes involved in the cellular uptake processes, endo-
somal escape, or other mechanisms.[28] The results of this study 
demonstrate the great potential of the DMA platform in minia-
turized high-throughput drug screenings, high-throughput cell 
transfection experiments, and search for new biologically active 
molecules.
3. Conclusion
In this study, we systematically screened the effect of 774 
FDA-approved drugs and their concentrations on transfection 
efficiency in three different cell types. Based on the primary 
screening, 14 hit compounds were selected and further evalu-
ated and validated on the droplet microarray platform as well as 
both in 384- and 96-well plates. Several compounds (auranofin, 
carbidopa, captopril, hydrocortisone acetate, ifosfamide, inda-
pamide, oxacillin sodium salt monohydrate, methylpred-
nisolone, naphazoline·HCl, rifampin, oxiconazole nitrate, 
piroxicam, tranylcypromine hemisulfate, and rivastigmine 
tartrate) showed up to fivefold increase of transfection effi-
ciency, which can be important for the fundamental research 
projects but also for the production of therapeutically relevant 
proteins. Our results also demonstrate the power of the droplet 
microarray platform in miniaturized high-throughput experi-
ments. In this study, we performed in total around 42 000 indi-
vidual experiments using 20 nL droplets, which resulted in only 
0.84 mL of total cell suspension and required only 200 pmoles 
of drugs (total 0.02 moles). This is 2500 times smaller than if 
the same experiment would have to be performed in 384-well 
plates (Figure 2C).
4. Experimental Section
Materials: Formaldehyde solution, Thermo Scientific Shandon Immu-
Mount, Hoechst 33 342 (1.0 mg mL−1 in water) and propidium iodide 
(PI, 1.0 mg mL−1 in water) were purchased from Thermo Fisher Scientific 
Inc. (MA, USA). ScreenFectA transfection reagent was obtained from 
ScreenFect (Eggenstein-Leopoldshafen, Germany). Fetal calf serum 
(FCS), RPMI-1640 cell culture medium, 0.25% trypsin/EDTA, Dulbecco’s 
Modified Eagle’s Medium (DMEM), 1% penicillin/streptomycin solution 
were purchased from Gibco, Life Technologies GmbH (Darmstadt, 
Germany). Ham’s F12 medium was purchased from Biowest (Nuaillé, 
France).
Droplet Microarray: The DMA slides were purchased from Aquarray 
(Aquarray, Eggenstein-Leopoldshafen, Germany) and they were sterilized 
in absolute ethanol for 60 min ensuing drying on the cell culture bench 
before using.
Cell Culture: Jurkat human T-cell lymphocyte cells were maintained 
in RPMI-1640 cell culture medium supplemented with 10% heat-
inactivated FCS and 1% penicillin/streptomycin at 37 °C in a 5% CO2 
incubator. Chinese hamster ovary CHO-K1 cells were cultured in 
Ham’s F12 medium supplemented with 10% FCS at 37 °C in a 5% CO2 
humidified atmosphere. Cells were trypsinized using 0.25% trypsin/
EDTA and were regularly split to keep them in the logarithmic phase of 
growth. Human embryonic kidney 293T (HEK293T) cells were cultured 
in complete DMEM supplemented with 10% fetal calf serum at 37 °C 
in a 5% CO2 humidified incubator. Cells were trypsinized using 0.25% 
trypsin/EDTA and were regularly split to keep them in the logarithmic 
phase of growth.
GFP Plasmid DNA Preparation: A plasmid encoding for green 
fluorescent protein (pGFP) was used as a reporter gene to monitor 
the results of gene transfection. Highly purified covalently closed 
circular plasmid DNA was isolated by plasmid purification mini and 
maxi kits from Qiagen (Valencia, CA) according to the manufacturer’s 
instructions. The final concentration of DNA was 0.5–2.0 µg µL−1 and 
the A260/A280 value was above 1.8. Prepared plasmid DNA was stored at 
−20 °C for further using.
Drug Library: The Screen-Well FDA-approved drug library V2, 
consisting of 774 compounds, was provided as 10 × 10−3 m stock 
solutions in dimethyl sulfoxide (BML-2843 Version 1.2; Enzo Life 
Sciences, Albany, NY, USA) and arrayed in a total 11 96-well plate, 
leaving the first and last columns in each plate for controls. Each drug 
solution in these microplates was diluted with sterile water to produce 
100 × 10−6 m prediluted plates. The prediluted drug plates were sealed 
and stored at −80 °C.
Printing: FDA-approved drug library was preprinted into each spot on 
DMA at various concentrations and volumes using sciFLEXARRAYER 
S11 dispenser (Scienion AG, Berlin, Germany) followed by drying in a 
desiccator under 50 mbar vacuum overnight. Since small volumes (2 nL 
for 1 × 10−6 m group, 2 nL for 10 × 10−6 m,, and 6 nL for 100 × 10−6 m 
group) were printed, the droplets evaporate much faster than cell 
droplets. Therefore, to make all the conditions the same, the drugs 
need to be dried before transfection. After that, cells with or without 
transfection reagents were printed onto DMA by I-DOT One noncontact 
dispenser (Dispendix GmbH, Stuttgart, Germany) which is equipped 
with a powerful humidifier and a hygrometer. The humidity was set to 
70% at 25 °C. As soon as humidity reached 70%, it started to print cells. 
After cell printing, the DMA slides were placed into a 10 cm petri dish 
with 3 mL of phosphate-buffered saline and a wet humidifying pads in 
the upper lid to prevent evaporation during incubation.
Screening Protocol: For the primary screening, the FDA-approved drug 
library was obtained in 10 × 10−3 m stock solution of DMSO and diluted 
with sterile water to produce 100 × 10−6 m prediluted plates. To do that, 
compounds were printed on 500 µm DMA. Then the DMA slides were 
dried in a desiccator under 50 mbar vacuum overnight. The positive 
control (drug-free) was set as gene transfection without any compound 
but in the presence of equivalent of DMSO. From the primary screening, 
14 compounds were selected for validation and were prediluted as 
indicated for the primary screening. Validation was performed on 1 mm 
DMA and 384-well plate with the same protocol for primary screening, 
except cells on DMA were stained with Hoechst 33 342 to visualize 
cell nucleus and propidium iodide (PI) to distinguish dead cells. For 
confirmation, 4 compounds were picked and delivered in 96-well plates 
and tested in diverse parameters.
In Vitro Transfection: Transfection on 500 µm DMA: the 774 FDA-
approved drugs were printed on the DMA at certain volumes and dried 
in the vacuum desiccator overnight. Complexes of GFP plasmid DNA and 
ScreenFectA transfection reagent were prepared with 0.3 µL ScreenFectA 
in 10 µL ScreenFect dilution buffer, followed by diluting a total of 300 ng 
GFP plasmid DNA in dilution buffer to a final volume of 10 µL. The two 
mixtures prepared above were then immediately mixed using rapidly 
slight pipette strokes and incubated for 20 min at room temperature 
for complex formation. After that, 80 µL fresh cell suspension at a 
concentration of 2 × 106 cells mL−1 were added to complexes and gently 
mixed with pipette. Then, the mixture was printed onto 500 µm DMA 
20 nL per spot using I-DOT One Non-Contact Dispenser (Dispendix 
GmbH, Stuttgart, Germany) followed by a further 24 h incubation in 
the cell culture incubator. After that, formaldehyde solution was printed 
into each DMA spot to fix the cells before add immu-mount medium to 
mount cells on DMA followed by dried at 4 °C. Images of the individual 
spots were taken using the Olympus IX81 inverted motorized microscope 
(Olympus, Tokyo, Japan) and Keyence BZ-9000 microscope (KEYENCE, 
Osaka, Japan). Transfection efficiency was assessed after 24 h incubation. 
The transfection efficiency was quantified by counting the GFP positive 
cell numbers using Image J (https://imagej.nih.gov/ij/).
Transfection on 1 mm DMA: the transfection process was the same 
with the method described above. Briefly, the FDA-approved drugs 
were printed onto 1 mm DMA at certain volumes. Complexes of GFP 
plasmid DNA and ScreenFectA transfection reagent were prepared 
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with 0.15 µL ScreenFectA in 10 µL ScreenFect dilution buffer, followed 
by diluting a total of 150 ng GFP plasmid DNA in dilution buffer to 
a final volume of 10 µL. The two mixtures prepared above were then 
immediately mixed using rapidly slight pipette strokes and incubated for 
20 min at room temperature for complex formation. After that, 80 µL 
fresh cell suspension at a concentration of 1.25 × 106 cells mL−1 were 
added to complexes and gently mixed with pipette. Then, the mixture 
was printed onto 1 mm DMA 100 nL per spot using I-DOT One Non-
Contact Dispenser (Dispendix GmbH, Stuttgart, Germany) followed by 
a further 24 h incubation in the cell culture incubator. Then, 50 nL per 
spot of Hoechst 33 342 (33.3 µg mL−1) and PI (2.22 µg mL−1) solution 
was printed into each spot. The 1 mm DMA slide was placed into a 
standard 10 cm petri dish equipped with a humidifying pad to prevent 
evaporation for 15 min. Images of the individual spots were taken using 
the Olympus IX81 inverted motorized microscope (Olympus, Tokyo, 
Japan). The number of GFP positive, Hoechst 33 342 and PI positive 
cells were counted using Image J. Cell viability was calculated as the 
following equation: cell viability (%) = 1 – (PI-positive cell numbers/
Hoechst positive cell numbers) × 100. The transfection efficiency was 
calculated as the following equation: transfection efficiency (%) = (GFP 
positive cell numbers/Hoechst positive cell numbers) × 100.
Transfection in 384-well plate: The transfection process was the same 
as the method described above. Briefly, the FDA-approved drugs were 
pipetting into 384-well plates at certain volumes prior to overnight 
drying in the vacuum desiccator. Complexes of GFP plasmid DNA 
and ScreenFectA transfection reagent were prepared with 0.017 µL 
ScreenFectA in 10 µL ScreenFect dilution buffer, followed by diluting 
a total of 17 ng GFP plasmid DNA in dilution buffer to a final volume 
of 10 µL. The two mixtures prepared above were then immediately 
mixed using rapidly slight pipette strokes and incubated for 20 min at 
room temperature for complex formation. After that, 80 µL fresh cell 
suspension at a concentration of 7.13 × 104 cells mL−1 were added 
to complexes and gently mixed with pipette. Then, the mixture was 
manually seeding into each well at the volume of 20 µL followed by a 
further 24 h incubation in the cell culture incubator. Then, 2 µL per well 
Hoechst 33 342 (100 µg mL−1) and PI (6.67 µg mL−1) solution was added 
into each well and incubated for 15 min. Nine images of the individual 
well were taken using the Olympus IX81 inverted motorized microscope 
(Olympus, Tokyo, Japan). The number of GFP positive, Hoechst 33 342 
and PI positive cells were counted using Image J. Cell viability was 
calculated as the following equation: cell viability (%) = 1 – (PI-positive 
cell numbers/Hoechst positive cell numbers) × 100. The transfection 
efficiency was calculated as the following equation: transfection efficiency 
(%) = (GFP positive cell numbers/Hoechst positive cell numbers) × 100.
Transfection in 96-well plate: The transfection process was the same 
as the method described above. Briefly, the FDA-approved drugs were 
pipetting into 96-well plates at certain volumes prior to overnight 
drying in the vacuum desiccator. Complexes of GFP plasmid DNA and 
ScreenFectA transfection reagent were prepared with 0.1, 0.2, 0.3, and 
0.4 µL ScreenFectA in 10 µL ScreenFect dilution buffer, respectively, 
followed by diluting a total of 50, 75, and 100 ng GFP plasmid DNA in 
dilution buffer to a final volume of 10 µL. The two mixtures prepared 
above were then immediately mixed using rapidly slight pipette 
strokes and incubated for 20 min at room temperature for complex 
formation. After that, 80 µL fresh cell suspension at a concentration of 
3.75 × 105 cells mL−1 were added to complexes and gently mixed with 
pipette. Then, the mixture was manually seeding into each well at the 
volume of 100 µL followed by a further 24 h incubation in the cell culture 
incubator. Then, 10 µL per well Hoechst 33 342 (100 µg mL−1) and PI 
(6.67 µg mL−1) solution was added into each well and incubated for 
15 min. 16 images of the individual well were taken using the Olympus 
IX81 inverted motorized microscope (Olympus, Tokyo, Japan). The 
number of GFP positive, Hoechst 33 342 and PI-positive cells were 
counted using Image J. Cell viability was calculated as the following 
equation: cell viability (%) = 1 – (PI-positive cell numbers/Hoechst 
positive cell numbers) × 100. The transfection efficiency was calculated 
as the following equation: transfection efficiency (%) = (GFP positive cell 
numbers/Hoechst positive cell numbers) × 100.
Data Analysis and Statistics: Data were presented as mean ± standard 
deviation (SD). The statistical significance of the experimental data were 
determined with a two-tailed Student t-test (p-value < 0.05) and the 
initial hits cut-off was set as control mean + 3SD.
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